67-6

46/93

554chial needle aspiration. J Thorac Dis. 2019; 11: 2175-2180. 11) Shukuya T, Yamada T, Koenig MJ, Xu J, Okimoto T, Li F, Amann JM, Carbone DP: The Effect of LKB1 Activity on the Sensi-tivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer. J Thorac Oncol. 2019; 14: 1061-1076.† 12) Hidayat M, Mitsuishi Y, Takahashi F, Tajima K, Yae T, Miyahara K, Hayakawa D, Winardi W, Ihara H, Koinuma Y, Wirawan A, Nurwidya F, Kato M, Kobayashi I, Sasaki S, Takamochi K, Hayashi T, Suehara Y, Moriyama M, Mori-yama H, Habu S, Takahashi K: Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer. Bosn J Basic Med Sci. 2019; 19: 335-367. 13) Kadoya K, Togo S, Tulafu M, Namba Y, Iwai M, Watanabe J, Okabe T, Jin J, Kodama Y, Kitamura H, Ogura T, Kitamura N, Ikeo K, Takeda T, Kondo N, Takahashi K: Specific features of fibrotic lung fibroblasts highly sensitive to fibrotic processes mediated via TGF-β-ERK5 interaction. Cell Physiol Biochem. 2019; 52: 822-837. 14) Jin J, Togo S, Kadoya K, Tulafu M, Namba Y, Iwai M, Watanabe J, Nagahama K, Okabe T, Hidayat M, Kodama Y, Kitamura H, Ogura T, Kitamura N, Ikeo K, Sasaki S, Tominaga S, Takahashi K: Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1. Respir Res. 2019; 20: 119. 15) Zuoyou L, Shiota S, Morio Y, Sugiyama A, Sekiya M, Iwakami SI, Ienaga H, Fukuchi Y, Takahashi K: Borderline pulmonary hyper-tension associated with chronic hypercapnia in chronic pulmonary disease. Respir Physiol Neurobiol. 2019; 262: 20-25.＊ 16) Tsutsumi T, Nagaoka T, Yoshida T, Wang L, Kuriyama S, Suzuki Y, Nagata Y, Harada N, Kodama Y, Takahashi F, Morio Y, Takahashi K: Nintedanib ameliorates experimental pulmo-nary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation. PLoS One. 2019; 14: e0214697. 17) Kato M, Sasaki S, Nakamura T, Kurokawa K, Yamada T, Ochi Y, Ihara H, Takahashi F, Takahashi K: Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis. Sci Rep. 2019; 9: 12062. 18) Karasutani K, Baskoro H, Sato T, Arano N, Suzuki Y, Mitsui A, Shimada N, Kodama Y, Seyama K, Fukuchi Y, Takahashi K: Lung Fixation under Constant Pressure for Evalu-ation of Emphysema in Mice. J Vis Exp. 2019; 151: e58197. 19) Ihara H, Kikuchi K, Taniguchi H, Fujita S, Tsuruta Y, Kato M, Mitsuishi Y, Tajima K, Kodama Y, Takahashi F, Takahashi K, Azuma N: 23-valent pneumococcal polysaccharide vaccine improves survival in dialysis patients by preventing cardiac events. Vaccine. 2019; 37: 6447-6453. 20) Tateishi K, Ko R, Shukuya T, Okuma Y, Watanabe S, Kuyama S, Murase K, Tsukita Y, Ashinuma H, Nakagawa T, Uematsu K, Nakao M, Mori Y, Kaira K, Mouri A, Miyaba-yashi T, Sakashita H, Matsumoto Y, Tani-gawa T, Koizumi T, Morita S, Kobayashi K, Nukiwa T, Takahashi K: North East Japan Study Group. Clinical Outcomes of Second-Line Chemotherapy in Patients with Previ-ously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study. Oncologist. 2019; 0593. doi: 10.1634. 21) Kitajima S, Ivanova E, Guo S, Yoshida R, Campisi M, Sundararaman SK, Tange S, Mitsuishi Y, Thai TC, Masuda S, Piel BP, Sholl LM, Kirschmeier PT, Paweletz CP, Watanabe H, Yajima M, Barbie DA: Suppres-sion of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer. Cancer Discov. 2019; 9: 34-45. 22) Koike K, Berdyshev EV, Mikosz AM, Bronova IA, Bronoff AS, Jung JP, Beatman EL, Ni K, Cao D, Scruggs AK, Serban KA, Petrache I: Role of Glucosylceramide in Lung Endothelial Cell Fate and Emphysema. Am J Respir Crit Care Med. 2019; 200: 1113-1125. 23) Shoji T, Konno S, Niida Y, Ogi T, Suzuki M, Shimizu K, Hida Y, Kaga K, Seyama K, Naka T, Matsuno Y, Nishimura M: Familial multi-focal micronodular pneumocyte hyperplasia with a novel splicing mutation in TSC1: Three